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Imagine a deck of new cards perfectly sequenced from One
of Clubs to the Ace of Spades. Shuffle once (overhand
method), and most cards are still in order, e.g., . . . 9, 10,
Jack, King, Queen, Ace of Spades. Shuffle twice, three
times, and so on and more and more randomness is intro-
duced into the deck. Cards that are juxtaposed next to one
another, e.g., King and Ace of Spades will likely travel to-
gether through multiple shufflings as a card has to be pre-
cisely inserted between the two for the arrangement to be
disrupted. But, the One of Spades is likely to fall out of
sequence relative to the Ace of Spades early in the shuffling
process as the likelihood that a random card is inserted
between a One and Ace is quite high. Thus, even in a simple
game of cards, near neighbors travel together for longer
periods of time and much more shuffling is required to sep-
arate the two than far neighbors.
Now, it is even mathematically possible to position the
cards based on the number of shuffles required to disrupt
their relative position. In the case of Spades, it would, by
definition, take only one shuffle to misalign the One from the
Ace (N¼ 1). It is possible that four shuffles later (N¼ 4), the
Jack–Queen–King–Ace sequence would no longer be in-
tact. But it would take a very large N to separate the King
from the Ace. In other words, the number of shuffles (N) it
takes to randomize the order between any two cards is
inversely proportional to the distance between the two
cards, e.g., N¼1 for One–Ace; N¼4 for Jack–Ace; and
possibly N¼30 for King–Ace. What do cards have to do
with a BRAF paper? By analogy, the ancestral human gen-
ome is not unlike a sequenced deck of cards; over time,
recombination shuffles the order. But, the human genome is
not old enough to allow the entire genome to be shuffled.
Short runs of genetic material continue to travel as neigh-
bors much in the same way the King/Ace survives its part-
nership through multiple rounds of shuffling. In genetic
terms, this is called linkage disequilibrium (LD), as two
markers have maintained their association because of their
proximity to one another, structural considerations that
minimize recombination, or undisclosed selection pressure,
to retain these two markers in contiguity.
The paper by James et al (2005) in this issue of the JID
posits a simple hypothesis and sets out to find supportive
evidence. It has been known for a couple of years now that
somatic mutations in BRAF are quite common in nevi and
melanoma (Davies et al, 2002; Pollock et al, 2003). Subse-
quent to those results, several groups have launched efforts
to find germline melanoma risk signatures in BRAF. Re-
cently, in a large German case–control study of 502 mel-
anoma cases and 450 controls, Meyer et al (2003) found
some association between intronic BRAF single nucleotide
polymorphisms (SNPs) and melanoma risk. A smaller study
of 80 melanoma cases and 91 controls failed to reveal any
association between intronic variants and melanoma risk
(Laud et al, 2003). Unfortunately, conflicting data such as
these are quite commonplace in our initial attempts at find-
ing low-to-medium risk genes for complex disorders.
In genetic association studies, researchers rely on LD
between a phenotype-causing variant and a neighboring
marker to predict risk. In the article by James et al (2005),
the association with BRAF polymorphisms holds biological
and mathematical plausibility; however, the actual mel-
anoma-risk variant remains to be identified. Thus, a genetic
and biochemical mechanism for the observed findings is
still unavailable. It is likely that the exact causative change
lies within a segment of DNA containing BRAF. Segments of
DNA that are shared by multiple individuals, such as mel-
anoma cases, arise because of an absence of recombina-
torial shuffling between the causative variant and marker
(remember King/Ace). These segments are termed haplo-
types. There is an ongoing effort now to map all of the var-
ious haplotypes common to humans (HapMap project:
http://www.hapmap.org/index.html). The advantage of us-
ing LD mapping is that it reduces the complexity of the
human genome. For instance, in the study by James et al
(2005), the 16 BRAF SNPs could be reduced to three major
haplotypes accounting for 98% of the chromosomes. In
theory, most tightly linked haplotypes are defined by a sin-
gle or a few SNPs and thus, large-scale association studies
could be reduced to a few choice ‘‘tag’’ SNPs that represent
the haplotype block. Great in theory, but many more studies
are needed to substantiate this methodological paradigm.
There are several concepts that are worthy of mention in
relation to the BRAF article in this issue.
1. Coding versus noncoding bias. There are two schools of
thought behind disease-predisposing alleles. One group
favors the idea that sequence variants in exons or peri-
exonic regions modify protein levels or function and are,
thus, primarily responsible for disease risk. There is am-
ple reason to accept these tenets as heritable deleteri-
ous mutations are diagnostic of most monogenic
Mendelian disorders. But the other group sees the en-
tire genome as a source of disease risk and alterations in
the intronic region as potentially affecting expression;
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thus, noncoding SNPs are as likely to predispose to dis-
ease as coding SNPs. The study by James et al certainly
falls into this category, as most of the SNPs examined fall
into intronic regions. This search is not unreasonable as
the hypothesis is sound and several studies have already
exonerated BRAFV600E as a germline melanoma-sus-
ceptibility allele (Lang et al, 2003; Laud et al, 2003).
2. More is better. With monogenic disorders, it is not in-
conceivable that a new disease paradigm becomes es-
tablished by identifying the causative mutation in a single
pedigree. But with more common, complex disorders,
the larger the population sampled, the more robust the
results. The Australian melanoma studies derive tremen-
dous power from their sample size. As melanoma holds
such a large disease burden in Australia, it is quite fitting
that a study of this magnitude be conducted in that
continent. In SNP association studies, a small sample
size is highly vulnerable to false positives. Such was
probably the case of the EGF promoter variant and me-
lanoma risk, in which an early, smaller study detected an
association between a functional polymorphism in the
EGF promoter (Shahbazi et al, 2002) and melanoma;
subsequently, three larger studies could not confirm this
finding (McCarron et al, 2003; Amend et al, 2004; James
et al, 2004; Randerson-Moor et al, 2004). Thus, size is
critical in association studies.
3. Multiple comparisons. The a level is the chance taken by
researchers to incorrectly declare a difference, effect, or
relationship to be true because of chance. Customarily,
the a level is set at 0.05, or, in no more than one in 20
statistical tests the test will detect ‘‘something,’’ whereas
in fact there is nothing. In comparing SNP frequencies
between cases and controls, each genotype can be
considered an individual test. In five tests the chance of
finding at least one difference or relationship significant
because of chance fluctuation equals 0.22, or one in five.
In 10 tests this chance increases to 0.40, which is about
one in two. The latest SNP Chip from Affymetrix packs
100,000 SNPs into one assay so the likelihood of de-
claring a Type I error is tremendous unless some cor-
rection is made. A traditional approach is to use the
Bonferroni correction. Using this method, the a level of
each individual test is adjusted downward to ensure that
the overall (experiment-wise) risk for a number of tests
remains 0.05. Practically speaking, the p value is divided
by the N number of comparisons. For 100,000 SNPs, a
significant p value is roughly approximated by 0.05/
100,000–0.0000005. It is unlikely that any single SNP will
ever approach this level of significance. Moreover, it is
likely that the Bonferroni correction is too punitive for
most genetics studies. In multiple comparisons, the in-
dividual tests should be independent of each other for a
full correction. This is unlikely the case as there is large-
scale LD. In other words, SNPs travel together and
should not represent completely independent entities.
Population geneticists are still struggling with mathe-
matical methods to correct for multiple comparisons. It
remains one of the central challenges in the search for
disease markers. An alternative method used by James
et al is to perform permutation simulation. Here, cases
and controls are randomly permutated in status by a
computer program. If the distribution of SNPs observed
between cases and controls occurs 23 times out of 1000
permutations, for instance, then p¼ 0.023. In the James
et al article, 11 SNPs exceeded the threshold for statistical
significance at p¼0.05; but, after correction for multiple
testing by permutation, the best p value was 0.065.
For geneticists, p values have slightly different connota-
tions than for clinical trialists. Often, a drug is deemed
ineffective if ‘‘p is not less than 0.05.’’ Obviously, these
numbers have significant therapeutic and commercial im-
plications. But if the goal is to identify a biologically plau-
sible, replication-competent genetic disease marker, it is
absolutely essential to filter out the noise from the signal.
These days, genotyping, to a certain extent, has become
secondary to the mathematical rigor needed to interpret the
results. How we filter out noise without sacrificing signal is
the crux of the challenge. But replication in independent,
well-powered studies will still remain the gold standard of a
bona fide signal from noise.
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